PKU GOLIKE Debuts at SSIEM 2018 Conference: Science Driven Innovation behind the Medical Food for PKU Management of APR Applied Pharma Research
APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, has successfully concluded its participation at the recent SSIEM (Society for the Study of Inborn Errors of Metabolism) Conference held in Athens. The company has taken advantage of this international event, gathering around 3.000 physicians involved in inherited metabolic diseases, to showcase PKU GOLIKE®, the innovative Phenylalanine (Phe)-free medical food formula for Phenylketonuria (PKU), powered by the patented Physiomimic Technology TM .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180913005450/en/
PKU GOLIKE. Feel the change: Join the evolution in nutritional management (Photo: APR Applied Pharma Research)
PKU GOLIKE® is a brand new generation of medical food formulas for oral use consisting of a prolonged released amino acid (AA) mixture without Phe (with or without vitamins and minerals), providing a physiological absorption of the AAs as well as a remarkable masking of odor and taste, while minimizing the unpleasant after-taste typical of free AAs.
The large attendance at APR’s sponsored satellite symposium “Physiological Absorption of Amino Acids: Rationale and Expected Benefits”, involving renown international experts in PKU, represented the ideal occasion to divulge details regarding PKU GOLIKE® and the Physiomimic TechnologyTM . During the symposium, it was highlighted how this drug delivery technology can effectively prolong the release of the amino acids (AAs) and support their physiological absorption.
In particular, a study in human subjects demonstrated that significant reductions of the AAs absorption peaks were obtained with PKU GOLIKE®, when compared with the same AAs mixture without the application of the technology. The reduction of the absorption peaks, associated with a similar bioavailability of the AAs, allows reducing AA fluctuations in favor of an improved efficiency in the use of AAs.
The same cross over human study also demonstrated a reduction of Phe fluctuations over time, deriving from body metabolism of the study subjects receiving Phe-free PKU GOLIKE® in fasting conditions, with respect to the fluctuations measured when free AAs were consumed.
Overall, the scientific data of PKU GOLIKE® presented at this meeting open new avenues for research in nutrition, aimed at providing data useful to patients to improve the efficiency of the dietary management of their disorder.
Throughout the lifetime of the event, APR’s staff has been very busy at the company booth with welcoming a high number of physicians from all over the world eager to gather more information about PKU GOLIKE®. Visitors’ questions regarded, in particular, the patented Physiomimic™ Technology - how it works and the benefits of its application to the innovative amino acids mixture. They also had the chance to get to know PKU GOLIKE® range, made of three different AA mixes suitable for PKU patients of different ages, as well as to experience the special coating micro granules containing the exclusive formulation of AAs.
Physicians and dieticians who tasted the product were extremely surprised to find out how the Physiomimic Technology TM is actually able to remarkably mask the unpleasant taste and odor of AAs, thus being confirmed on the extent of this significant advantage for PKU patients’ compliance to dietary regimen.
The venue offered also the opportunity to arrange several meetings with potential business partners, who could appraise the extent of the company innovation appeal and be informed about APR’s projects in the inherited metabolic diseases.
“We are very pleased by the positive reactions of the medical community to our innovation. As father of a PKU child, I was quite conscious of the clinical and nutritional gaps in PKU management still unresolved. We decided to apply our deep know-how in drug delivery technologies and systems to offer to PKU patients’ a new treatment option, the benefits of which are confirmed by the preclinical and clinical data generated so far.” said Paolo Galfetti, CEO of APR Applied Pharma Research. “Now, we look forward to take to fruition of PKU patients and care givers this innovative product line and to further support our innovation by generating additional scientific data in the coming future”.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“Phe”), an essential amino acid found in most protein-containing food. Excessive amounts of Phe in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-Phe) dietetic treatment combined with a daily assumption of low-protein modified foods and medical food, which provides Phe-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharmaproducts/medical-prescription/genetic-metabolic-disease/
APR Applied Pharma Research s.a.:
Paolo Galfetti, +41 91 6957020
Chief Executive Officer
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Sintavia Announces Joint Venture with Howco Group21.5.2019 18:00:00 EEST | Tiedote
Sintavia, LLC, the leading Tier One metal additive manufacturer for the Aerospace & Defense industry, announced today that it had signed a term sheet to form a joint venture with Howco Group in support of the development of additive manufacturing within the Oil & Gas industry. The joint venture would be branded under the Howco Group name and be co-located at Howco’s North American headquarters in Houston, Texas. It is expected that the joint venture will commence operations later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521005062/en/ Brian Neff, Sintavia's Founder and CEO and David Preston, Executive Vice President at Howco Group, sign a term sheet to form a joint venture in support of the development of additive manufacturing within the Oil & Gas industry. (Photo: Business Wire) “Many of the proprietary additive manufacturing processes that Sintavia has developed for the Aerospace & Defense industry appl
ZOOM announces Elevēo WFM21.5.2019 17:56:00 EEST | Tiedote
ZOOM International, the leader in driving customer experience through the emotion of the customer, today takes a major step in the Workforce Engagement Management market with the release of the Elevēo platform including the new Elevēo WFM. This announcement represents the culmination of two major milestone initiatives for ZOOM International, the release of a new Workforce Management product as well as their first native cloud platform “as a Service offering”. Unlike other companies that continue to expand via mergers and acquisitions, Elevēo was created by ZOOM to ensure an optimized workflow and ease of use. Our industry is fragmented, and we wanted to help customers expand from spreadsheets and multiple vendors to one. Forecasting and Scheduling Simplified Anyone who works in a contact center will agree that administratively, managing a workforce is difficult, time consuming, and counter intuitive by nature. Even when the “herding cats” element of agents self-scheduling is removed, t
Andersen Global Signs First Agreement in Bahrain21.5.2019 16:30:00 EEST | Tiedote
Andersen Global today announced its first collaboration agreement in Bahrain with independent consulting firm Awael Al Bahrain Management Consultancy (Awael). Andersen Global is committed to building a strong and effective practice in the Middle East and the collaboration with Awael is the next step in this process. Abbas Radhi founded Awael in 2014 as an alternative to the Big Four consulting firms. Awael’s growing team of professionals serves a wide range of business clients including owner-managed businesses. Due to the quality of the Awael professional team, larger businesses are starting to approach Awael for the provision of services. The firm’s practice areas include accounting, tax, litigation support, corporate governance, independent directorship of listed and family owned companies, enterprise risk management, risk consulting, corporate finance, feasibility studies, family business support, management consulting, and corporate governance assessments. “Providing service of th
Kymeta Announces S. Douglas Hutcheson as Executive Chairman, Board of Directors, and Walter Z. Berger as President, CFO, and COO21.5.2019 16:00:00 EEST | Tiedote
Kymeta—the communications company that is completing the connectivity fabric for everything, everywhere—announced that S. Douglas Hutcheson is joining the Kymeta Board of Directors and will be named Executive Chairman and Walter Z. Berger has been hired as President, Chief Financial Officer (CFO), and Chief Operating Officer (COO). Hutcheson serves as Senior Advisor of Technology, Media and Telecom for Searchlight Capital and on several boards, both public and private. Previously, as CEO of Leap Wireless for nearly a decade, he oversaw the company’s operations and managed its eventual sale to AT&T. He brings extensive telecommunications and technology experience, having held several senior leadership positions at Leap after serving as an executive with Qualcomm. “Kymeta is leading the industry in hybrid communication solutions, and I’m excited to come on board as Executive Chairman,” said Doug Hutcheson, Kymeta Executive Chairman. “The telecommunications industry has made major strides
ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries21.5.2019 16:00:00 EEST | Tiedote
Remote monitoring and patient self-monitoring can drive CPAP adherence for people with sleep apnea, according to research presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS International Conference. Average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities. According to the new study, researchers found significantly higher rates when they evaluated patients on 100% cloud-connectable devices that enable remote monitoring: more than 31,000 Brazilians, 17,000 Mexicans, and 4.1 million Americans. Percent of study participants achieving 90-day PAP adherence (all Remotely and remotely monitored) self-monitored United States 74% 85% Brazil 72% 83% Mexico 66% 81% “These results equate a strong endorsement for remote and self-monitoring technology,” said study coauthor and ResMed Chief Medical Officer Car
Indo-MIM and Desktop Metal Announce Strategic Partnership to Accelerate the Global Adoption of Metal 3D Printing21.5.2019 16:00:00 EEST | Tiedote
Desktop Metal, the company committed to making metal 3D printing accessible to manufacturers and engineers, announced today a strategic partnership with Indo-MIM, the global leader and world’s largest supplier of Metal Injection Molding (MIM) precision-engineered products with over 100 million metal parts produced annually for leading global OEMs. Together, Desktop Metal and Indo-MIM will offer innovative solutions to enable companies around the world to design and produce metal additively manufactured parts at scale and shorten time to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521005489/en/ Powered by Single Pass Jetting, the Production System is the world's first and only metal 3D printing system for mass production that delivers the speed, quality, and cost-per-part needed to compete with traditional manufacturing processes. (Photo: Business Wire) As one of the first companies to deploy the Desktop Metal P
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme